A gay men in Nigeria said that he tested positive for HIV two months after losing access to a US-supplied drug that ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to beat back the virus and prevent new infections.

The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.

And other biotech news brought to you by The Readout.

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

Amy Grant meeting Bono at Charlie Peacock's house in 2002 to discuss the HIV/AIDS crisis. The queen of Christian pop is ...

The visit also served as an opportunity to explore how UNAIDS can support South Africa’s G20 Presidency and the country’s ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

The dapivirine ring was originally approved in July 2020 to reduce the risk for HIV-1 infection in women 18 years and older ...

Discover a study that has highlighted the potential importance of dietitian-led interventions in liver health. Learn more.